A randomized double-blind parallel-group study conducted under in-house blinding conditions to determine the efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Trial Profile

A randomized double-blind parallel-group study conducted under in-house blinding conditions to determine the efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Completed
Phase of Trial: Phase IV

Latest Information Update: 09 May 2017

At a glance

  • Drugs Aprepitant; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2009 Actual patient number (866) added as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Actual end date (Feb 2004) added as reported by ClinicalTrials.gov.
    • 01 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top